New Zealand researchers have created a selective inhibitor through the chemical modification of DNA molecules that can inhibit APOBEC3B, an enzyme in cancer cells that causes treatment resistance in tumors. The findings in the journal Organic & Biomolecular Chemistry suggest that the selective inhibitor could help lead to the development of a novel class of cancer treatments.
Selective inhibitor may curb treatment resistance in cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.